In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties

Molecules. 2022 Jan 13;27(2):491. doi: 10.3390/molecules27020491.

Abstract

Cannabigerol (CBG) is a minor non-psychoactive cannabinoid present in Cannabis sativa L. (C. sativa) at low levels (<1% per dry weight) that serves as the direct precursor to both cannabidiol (CBD) and tetrahydrocannabinol (THC). Consequently, efforts to extract and purify CBG from C. sativa is both challenging and expensive. However, utilizing a novel yeast fermentation technology platform, minor cannabinoids such as CBG can be produced in a more sustainable, cost-effective, and timely process as compared to plant-based production. While CBD has been studied extensively, demonstrating several beneficial skin properties, there are a paucity of studies characterizing the activity of CBG in human skin. Therefore, our aim was to characterize and compare the in vitro activity profile of non-psychoactive CBG and CBD in skin and be the first group to test CBG clinically on human skin. Gene microarray analysis conducted using 3D human skin equivalents demonstrates that CBG regulates more genes than CBD, including several key skin targets. Human dermal fibroblasts (HDFs) and normal human epidermal keratinocytes (NHEKs) were exposed in culture to pro-inflammatory inducers to trigger cytokine production and oxidative stress. Results demonstrate that CBG and CBD reduce reactive oxygen species levels in HDFs better than vitamin C. Moreover, CBG inhibits pro-inflammatory cytokine (Interleukin-1β, -6, -8, tumor necrosis factor α) release from several inflammatory inducers, such as ultraviolet A (UVA), ultraviolet B (UVB), chemical, C. acnes, and in several instances does so more potently than CBD. A 20-subject vehicle-controlled clinical study was performed with 0.1% CBG serum and placebo applied topically for 2 weeks after sodium lauryl sulfate (SLS)-induced irritation. CBG serum showed statistically significant improvement above placebo for transepidermal water loss (TEWL) and reduction in the appearance of redness. Altogether, CBG's broad range of in vitro and clinical skin health-promoting activities demonstrates its strong potential as a safe, effective ingredient for topical use and suggests there are areas where it may be more effective than CBD.

Keywords: anti-aging; antioxidant; cannabidiol; cannabigerol; cannabis; fermentation.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Cannabidiol / pharmacology
  • Cannabinoids / biosynthesis*
  • Cannabinoids / pharmacology*
  • Cannabinoids / therapeutic use
  • Cells, Cultured
  • Dermatitis, Contact / drug therapy
  • Dermatitis, Contact / etiology
  • Dermatologic Agents / pharmacology*
  • Dermatologic Agents / therapeutic use
  • Female
  • Gene Expression Regulation / drug effects
  • Healthy Volunteers
  • Humans
  • Inflammation / etiology
  • Inflammation / prevention & control
  • Male
  • Models, Biological
  • Propionibacteriaceae
  • Saccharomyces cerevisiae / genetics*
  • Skin / drug effects
  • Skin Aging / drug effects
  • Skin Irritancy Tests
  • Sodium Dodecyl Sulfate / toxicity
  • Tetradecanoylphorbol Acetate / adverse effects
  • Tissue Array Analysis
  • Ultraviolet Rays / adverse effects

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Cannabinoids
  • Dermatologic Agents
  • Cannabidiol
  • Sodium Dodecyl Sulfate
  • cannabigerol
  • Tetradecanoylphorbol Acetate

Supplementary concepts

  • Cutibacterium acnes subsp. acnes